Archive: March/April 2026
Feature Article
Is There an Optimal Sequential Order to Androgen Receptor Axis Therapeutics?
Abstract: The hormonal therapeutic landscape in prostate cancer has expanded greatly over the last few decades with the advent of abiraterone acetate and second-generation antiandrogens such […]
Highlights
Highlights in Multiple Myeloma
From the 2025 American Society of Hematology Annual Meeting December 6-9, 2025 • Orlando, Florida Teclistamab/Daratumumab Combination Improves Survival in Relapsed/Refractory Myeloma Progression-free survival (PFS) and […]
Advances in Drug Development
New Drugs for Relapsed or Refractory Multiple Myeloma
H&O What are the most recent drug approvals for relapsed or refractory myeloma? BD We have seen an influx of immunotherapies for relapsed or refractory myeloma […]
CLL in Focus
The Sequencing of Covalent and Noncovalent BTK Inhibitors in CLL
H&O What are the most important differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors? JW The covalent BTK inhibitors that have US Food and […]
Breast Cancer In Focus
Optimal Treatment for Metastatic HER2+ Breast Cancer
H&O How common is human epidermal growth factor receptor 2 (HER2) overexpression in metastatic breast cancer? ST Approximately 15% to 20% of all breast cancers are […]
Advances in LLM
When Will Circulating Tumor DNA Be Ready for Prime Time in Lymphoma?
H&O What are the potential uses of circulating tumor DNA (ctDNA) in lymphoma? MR The most impactful potential uses of ctDNA would be to improve outcomes […]
Clinical Update
The Role of LGR5 in Epithelial Cancer
H&O What are the limitations of current treatments for epithelial cancer? JYB Epithelial cancer, which affects the cells that line the organs, includes colorectal cancer, head […]
Letter From the Editor
Letter From the Editor: Living With Regret, as an Oncologist
Regret is something I rarely felt as a young man, but now that I’m older, I experience it more often than I’d like as an oncologist. […]